PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31974913-12	2020	CONCLUSION: Novel budesonide inclusion complex formulations improved microscopic damage and reduced colonic MPO activity and TNF-alpha levels.	Budesonide	18-28	tumor necrosis factor	Rattus norvegicus	125-134	
15967733-5	2005	Pretreatment with NAC partially prevented tumor necrosis factor alpha (TNFalpha) production induced by the low concentration of LPS, while pretreatment with budesonide totally prevented the increased production of TNFalpha, interleukin (IL)-1beta, IL-6, and monocyte chemoattractive protein (MCP)-1 after LPS challenge at both low and high concentrations.	Budesonide	157-167	tumor necrosis factor	Rattus norvegicus	214-222	
14718604-8	2004	In vivo, ciclesonide (intratracheal administration), des-CIC, and budesonide inhibited antigen-induced accumulation of eosinophils, protein, and tumor necrosis factor-alpha into the bronchoalveolar lavage fluid of ovalbumin-sensitized and -challenged Brown Norway rats with an ED(50) value ranging from 0.4 to 1.3 mg/kg, indicating similar potency, which suggests in vivo activation of the parent compound.	Budesonide	66-76	tumor necrosis factor	Rattus norvegicus	145-172	
29456664-8	2018	In the Jinwei Tang + budesonide and theophylline + budesonide groups, IL-8 and TNF-alpha expression was significantly decreased (P<0.05) and the HDAC2 level increased (P<0.05) compared with that in the COPD group.	Budesonide	21-31	tumor necrosis factor	Rattus norvegicus	79-88	
29456664-8	2018	In the Jinwei Tang + budesonide and theophylline + budesonide groups, IL-8 and TNF-alpha expression was significantly decreased (P<0.05) and the HDAC2 level increased (P<0.05) compared with that in the COPD group.	Budesonide	51-61	tumor necrosis factor	Rattus norvegicus	79-88	
31948528-12	2020	Compared with the model group, the low-, middle-, and high-dose asiaticoside groups and the budesonide group had significant improvement in the above symptoms of bronchopulmonary dysplasia, significant reductions in MLI, MDA level in lung tissue, serum levels of IL-6 and TNF-alpha, and miR-155 level in lung tissue (P<0.05), and significant increases in RAC, SOD level, and mRNA and protein expression of SOCS1 in lung tissue (P<0.05).	Budesonide	92-102	tumor necrosis factor	Rattus norvegicus	272-281	
29236548-10	2017	Furthermore, treatment with budesonide significantly decreased the levels of MDA, MPO, and XO in the lung and the levels of TNF-alpha, IL-1beta, IL-6, and neutrophil elastase, but increased IL-10 in the BALF, accompanied by significantly reduced levels of serum P-selectin and LFA-1 in rats.	Budesonide	28-38	tumor necrosis factor	Rattus norvegicus	124-133	
23158492-12	2012	Saussurea and inhaled budesonide synergistically inhibited the expression of MUC5AC, IL-8 and TNF-alpha.	Budesonide	22-32	tumor necrosis factor	Rattus norvegicus	94-103	
21621192-1	2011	OBJECTIVE: To evaluate the effect of different concentrations of inhaled budesonide on secretion of tumoral necrosis factor-alpha (TNF-alpha) and on ligature-induced alveolar bone loss in Wistar rats.	Budesonide	73-83	tumor necrosis factor	Rattus norvegicus	131-140